LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--May 12, 2006--BioSante Pharmaceuticals (AMEX:BPA - News) today reported product development highlights and financial results for the first quarter ended March 31, 2006.
"We were pleased to start the year by submitting our new drug application for Bio-E-Gel®, which we believe, if and when approved, may offer the lowest effective dose of estrogen on the market for the treatment of hot flashes," said Stephen M. Simes, BioSante's president and chief executive officer. "Also in the first quarter, positive data from pre-clinical trials with BioVant(TM), our calcium phosphate nanoparticle technology, demonstrated its effectiveness as an adjuvant for flu vaccines, including bird flu. Looking to the remainder of 2006, we aim to continue our success by initiating Phase III clinical studies of LibiGel® in female sexual dysfunction."
